These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 30618615)

  • 1. Changes in Monoaminergic Neurotransmission in an Animal Model of Osteoarthritis: The Role of Endocannabinoid Signaling.
    Mlost J; Wąsik A; Michaluk JT; Antkiewicz-Michaluk L; Starowicz K
    Front Mol Neurosci; 2018; 11():466. PubMed ID: 30618615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of endocannabinoid system in dopamine signalling within the reward circuits affected by chronic pain.
    Mlost J; Wąsik A; Starowicz K
    Pharmacol Res; 2019 May; 143():40-47. PubMed ID: 30831242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pain relief induces dopamine release in the rat nucleus accumbens during the early but not late phase of neuropathic pain.
    Kato T; Ide S; Minami M
    Neurosci Lett; 2016 Aug; 629():73-78. PubMed ID: 27369326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional differences in the regulation of dopamine and noradrenaline release in medial frontal cortex, nucleus accumbens and caudate-putamen: a microdialysis study in the rat.
    Cenci MA; Kalén P; Mandel RJ; Björklund A
    Brain Res; 1992 May; 581(2):217-28. PubMed ID: 1393530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of anandamide breakdown reduces pain and restores LTP and monoamine levels in the rat hippocampus via the CB
    Kędziora M; Boccella S; Marabese I; Mlost J; Infantino R; Maione S; Starowicz K
    Neuropharmacology; 2023 Jan; 222():109304. PubMed ID: 36341807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of reward-induced dopamine release in the nucleus accumbens in animal models of depression: Differential responses to drug treatment.
    Minami S; Satoyoshi H; Ide S; Inoue T; Yoshioka M; Minami M
    Neurosci Lett; 2017 May; 650():72-76. PubMed ID: 28432029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat.
    Gobert A; Rivet JM; Lejeune F; Newman-Tancredi A; Adhumeau-Auclair A; Nicolas JP; Cistarelli L; Melon C; Millan MJ
    Synapse; 2000 Jun; 36(3):205-21. PubMed ID: 10819900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of increased grooming behavior and motor activity with alterations in nigrostriatal and mesolimbic catecholamines after alpha-melanotropin and neuropeptide glutamine-isoleucine injection in the rat ventral tegmental area.
    Sánchez MS; Barontini M; Armando I; Celis ME
    Cell Mol Neurobiol; 2001 Oct; 21(5):523-33. PubMed ID: 11860189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of the endogenous cannabinoid system in the effects of alcohol in the mesolimbic reward circuit: electrophysiological evidence in vivo.
    Perra S; Pillolla G; Melis M; Muntoni AL; Gessa GL; Pistis M
    Psychopharmacology (Berl); 2005 Dec; 183(3):368-77. PubMed ID: 16228194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microglia disrupt mesolimbic reward circuitry in chronic pain.
    Taylor AM; Castonguay A; Taylor AJ; Murphy NP; Ghogha A; Cook C; Xue L; Olmstead MC; De Koninck Y; Evans CJ; Cahill CM
    J Neurosci; 2015 Jun; 35(22):8442-50. PubMed ID: 26041913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral and electrophysiological effects of endocannabinoid and dopaminergic systems on salient stimuli.
    Laricchiuta D; Musella A; Rossi S; Centonze D
    Front Behav Neurosci; 2014; 8():183. PubMed ID: 24904335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain-Derived Neurotrophic Factor in the Mesolimbic Reward Circuitry Mediates Nociception in Chronic Neuropathic Pain.
    Zhang H; Qian YL; Li C; Liu D; Wang L; Wang XY; Liu MJ; Liu H; Zhang S; Guo XY; Yang JX; Ding HL; Koo JW; Mouzon E; Deisseroth K; Nestler EJ; Zachariou V; Han MH; Cao JL
    Biol Psychiatry; 2017 Oct; 82(8):608-618. PubMed ID: 28390647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endogenous opioid activity in the anterior cingulate cortex is required for relief of pain.
    Navratilova E; Xie JY; Meske D; Qu C; Morimura K; Okun A; Arakawa N; Ossipov M; Fields HL; Porreca F
    J Neurosci; 2015 May; 35(18):7264-71. PubMed ID: 25948274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new aspect of chronic pain as a lifestyle-related disease.
    Senba E; Kami K
    Neurobiol Pain; 2017; 1():6-15. PubMed ID: 31194049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of injections of 6-OHDA into either nucleus accumbens septi or frontal cortex on spontaneous and drug-induced activity.
    Joyce EM; Stinus L; Iversen SD
    Neuropharmacology; 1983 Sep; 22(9):1141-5. PubMed ID: 6415508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders.
    van der Stelt M; Di Marzo V
    Eur J Pharmacol; 2003 Nov; 480(1-3):133-50. PubMed ID: 14623357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocannabinoid Regulation of Reward and Reinforcement through Interaction with Dopamine and Endogenous Opioid Signaling.
    Wenzel JM; Cheer JF
    Neuropsychopharmacology; 2018 Jan; 43(1):103-115. PubMed ID: 28653666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of methylenedioxymethamphetamine (MDMA, "Ecstasy") on monoaminergic neurotransmission in the central nervous system.
    White SR; Obradovic T; Imel KM; Wheaton MJ
    Prog Neurobiol; 1996 Aug; 49(5):455-79. PubMed ID: 8895996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of GBR 12909, a dopamine re-uptake inhibitor, on monoaminergic neurotransmission in rat striatum, limbic forebrain, cortical hemispheres and substantia nigra.
    Nissbrandt H; Engberg G; Pileblad E
    Naunyn Schmiedebergs Arch Pharmacol; 1991 Jul; 344(1):16-28. PubMed ID: 1663587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.